Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Jian Li Campian, Vaishali Kapoor, Kaylan Griffith, Anita Mahadevan, Andrea Collins, Sukrutha Thotala, Arijita Jash, Tong Hu, Byung Ha Lee, Donghoon Choi, Se Hwan Yang, Dennis Hallahan, Milan G Chheda, Dinesh Thotala | ||||||||||||
Title | Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma. | ||||||||||||
|
|||||||||||||
URL | https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e13516 | ||||||||||||
Abstract Text | Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NT-I7 | GX-I7|rhIL-7-hyFc|IL-7-hyFc|Efineptakin alfa|Hyleukin | NT-I7 is a fusion protein comprised of a recombinant interleukin-7 (IL-7) linked to a hybrid immunoglobulin Fc region, which potentially has increased stability and enhances anti-tumor immune response (Journal of Clinical Oncology 37, no. 15_suppl, Abs nr: e13516). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|